Coronary disease & ACS

Surveillance Stress Testing After Percutaneous Intervention for Patients With Multivessel or Left Main Coronary Disease

J Am Coll CardiolPublished Secondary analysis of the POST-PCI randomised trial

Primary resultResult — go to the resultHazard ratio 1.09 95% CI 0.68–1.74

Authors' conclusion

In high-risk patients with multivessel or left main CAD who underwent PCI, there was no incremental clinical benefit from routine surveillance functional-testing compared with standard care alone during follow-up.

Study context

Population
High-risk patients with multivessel or left main coronary artery disease (CAD) who underwent percutaneous coronary intervention (PCI)of 1,706 randomised
Participants
1,192 patients
Comparison
Routine functional testing at 1 year vs standard care alone
  • Functional testingn = 589
  • Standard caren = 603reference
Primary endpoint
Composite of:
  • All-cause death
  • MI
  • Hospitalisation for unstable angina
Follow-up
2 years

Primary result

As reported in the abstract

Hazard ratio

1.09

95% CI 0.68–1.74

P = 0.73

By group

Functional testingvs Standard care
HR 1.09 (95% CI 0.68–1.74); P = 0.73

Further findings

OutcomeHR (95% CI)P value
Primary outcome, multivessel disease (subgroup, n = 833) · 2 years1.09 (0.62–1.89)P = 0.78
Primary outcome, left main disease (subgroup, n = 359) · 2 years1.09 (0.46–2.56)P = 0.85
  • Primary outcome, multivessel disease (subgroup, n = 833): P for interaction = 0.90
  • Primary outcome, left main disease (subgroup, n = 359): P for interaction = 0.90

Invasive angiography and repeat revascularisation beyond 1 year

Increased rates with routine surveillance functional testing

Original publication

Surveillance Stress Testing After Percutaneous Intervention for Patients With Multivessel or Left Main Coronary Disease. J Am Coll Cardiol. Published 5 March 2024. doi:10.1016/j.jacc.2023.12.027

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.